Silo Pharma to Present at Proactive's One2One Virtual Investor Forum
Silo Pharma, a biopharmaceutical company, announced that CEO Eric Weisblum will present at Proactive's One2One Virtual Investor Forum on February 23, 2021, at 1 p.m. EST. The event is expected to reach Proactive's 20,000 YouTube subscribers and will be broadcasted globally. Silo Pharma focuses on merging traditional therapeutics with psychedelic research to address conditions such as depression, PTSD, and Parkinson's disease. The presentation will include a Q&A session and will be made available online after the event.
- None.
- None.
Englewood Cliffs, NJ, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as depression, PTSD, Parkinson’s, and other rare neurological disorders, announced today that Eric Weisblum, Chief Executive Officer will be presenting at Proactive's One2One Virtual Investor Forum on Tuesday, February 23, at 1 p.m. EST.
The Virtual One2One Investor Forum invitation will be sent to Proactive's estimated 20,000 YouTube subscribers and will be broadcasted internationally.
Mr. Weisblum’s presentation will be followed by a Q&A session and it will be published online.
For more information or to register for this event please visit https://www.proactiveinvestors.com.au/register/event_details/322
About Silo Pharma
Silo Pharma is a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as depression, PTSD, Parkinson’s, and other rare neurological disorders. Silo’s mission is to identify assets to license and fund the research which we believe will be transformative to the well-being of patients and the health care industry. For more information, visit www.silopharma.com .
Safe Harbor and Forward-Looking Statements
This news release contains "forward-looking statements" within the meaning of the “safe-harbor” provisions of the Private Securities Litigation Reform Act of 1995. These statements are identified by the use of words “could”, “believe”, “anticipate”, “intend”, “estimate”, “expect”, “may”, “continue”, “predict”, “potential” and similar expressions that are intended to identify forward-looking statements. Such statements involve known and unknown risks, uncertainties, and other factors that could cause the actual results of Silo Pharma, Inc. (“Silo” or “the Company”) to differ materially from the results expressed or implied by such statements, including changes to anticipated sources of revenues, future economic and competitive conditions, difficulties in developing the Company’s technology platforms, retaining and expanding the Company’s customer base, fluctuations in consumer spending on the Company’s products and other factors. Accordingly, although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company disclaims any obligations to publicly update or release any revisions to the forward-looking information contained in this presentation, whether as a result of new information, future events, or otherwise, after the date of this presentation or to reflect the occurrence of unanticipated events except as required by law.
Investor Relations Contact:
Hayden IR
Brett Maas
646-536-7331
Email: brett@haydenir.com
FAQ
What is the date and time of the Silo Pharma presentation?
Where can I watch the Silo Pharma presentation?
What topics will be covered in the Silo Pharma presentation?
How many subscribers does Proactive have for the One2One Virtual Investor Forum?
What is the focus of Silo Pharma as a biopharmaceutical company?
